These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 15117884)

  • 1. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic.
    Warner TD; Mitchell JA
    FASEB J; 2004 May; 18(7):790-804. PubMed ID: 15117884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Selective cyclooxygenase-2 (COX-2) inhibitors: importance and limitations].
    Pairet M; Netter P
    Therapie; 1999; 54(4):433-45. PubMed ID: 10667110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Preferential COX-2 inhibition: its clinical relevance for gastrointestinal non-steroidal anti-inflammatory rheumatic drug toxicity].
    Dammann HG
    Z Gastroenterol; 1999 Jan; 37(1):45-58. PubMed ID: 10091284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical pharmacology of selective COX-2 inhibitors.
    Capone ML; Tacconelli S; Sciulli MG; Patrignani P
    Int J Immunopathol Pharmacol; 2003; 16(2 Suppl):49-58. PubMed ID: 14552704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on cyclooxygenase inhibitors: has a third COX isoform entered the fray?
    Hersh EV; Lally ET; Moore PA
    Curr Med Res Opin; 2005 Aug; 21(8):1217-26. PubMed ID: 16083531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do non-steroidal anti-inflammatory drugs and COX-2 selective inhibitors have different renal effects?
    Giovanni G; Giovanni P
    J Nephrol; 2002; 15(5):480-8. PubMed ID: 12455713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective COX-2 inhibitors and gastrointestinal mucosal injury: pharmacological and therapeutic considerations.
    Dajani EZ; Agrawal NM
    J Assoc Acad Minor Phys; 2000; 11(2-3):28-31. PubMed ID: 10953541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Coxibs: cyclooxygenase-2 inhibitors].
    Turnheim K
    Wien Klin Wochenschr; 2001 Aug; 113(15-16):558-65. PubMed ID: 11571832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism of action of antiinflammatory drugs.
    Vane JR; Botting RM
    Int J Tissue React; 1998; 20(1):3-15. PubMed ID: 9561441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Valdecoxib: assessment of cyclooxygenase-2 potency and selectivity.
    Gierse JK; Zhang Y; Hood WF; Walker MC; Trigg JS; Maziasz TJ; Koboldt CM; Muhammad JL; Zweifel BS; Masferrer JL; Isakson PC; Seibert K
    J Pharmacol Exp Ther; 2005 Mar; 312(3):1206-12. PubMed ID: 15494548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect?
    Geis GS
    Scand J Rheumatol Suppl; 1999; 109():31-7. PubMed ID: 10422544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New NSAIDs and gastroduodenal damage.
    Folco GC
    Ital J Gastroenterol; 1996 Dec; 28 Suppl 4():28-9. PubMed ID: 9032579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Specific COX-2 inhibitors: prospects of therapy with new analgesic and anti-inflammatory substances].
    Hinz B; Brune K
    Wien Klin Wochenschr; 1999 Feb; 111(3):103-12. PubMed ID: 10093892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An introduction to aspirin, NSAIDs, and COX-2 inhibitors for the primary prevention of cardiovascular events and cancer and their potential preventive role in bladder carcinogenesis: part I.
    Moyad MA
    Semin Urol Oncol; 2001 Nov; 19(4):294-305. PubMed ID: 11769881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing.
    Jones MK; Wang H; Peskar BM; Levin E; Itani RM; Sarfeh IJ; Tarnawski AS
    Nat Med; 1999 Dec; 5(12):1418-23. PubMed ID: 10581086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Wound collagen deposition in rats: effects of an NO-NSAID and a selective COX-2 inhibitor.
    Muscará MN; McKnight W; Asfaha S; Wallace JL
    Br J Pharmacol; 2000 Feb; 129(4):681-6. PubMed ID: 10683192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [In vivo selectivity of nonsteroidal anti-inflammatory drugs on COX-1-COX-2 and gastrointestinal ulcers, in rats].
    Laudanno OM; Cesolari JA; Esnarriaga J; Flaherty P; Vada J; Guastalli G; San Miguel P; Bedini OA
    Acta Gastroenterol Latinoam; 1998; 28(3):249-55. PubMed ID: 9773153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical application of cyclooxygenase-2 inhibitors].
    Dzielska-Olczak M; Olczak S
    Pol Merkur Lekarski; 2001 Jun; 10(60):480-2. PubMed ID: 11503270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclooxygenase-2 selective and nitric oxide-releasing nonsteroidal anti-inflammatory drugs and gastric mucosal responses.
    Takeuchi K; Suzuki K; Yamamoto H; Araki H; Mizoguchi H; Ukawa H
    J Physiol Pharmacol; 1998 Dec; 49(4):501-13. PubMed ID: 10069692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Non-steroidal antiinflammatory drug--management of gastrointestinal complications and inhibition of COX-2].
    Tada Y; Nagasawa K
    Nihon Rinsho; 1999 Feb; 57(2):419-24. PubMed ID: 10078017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.